00:49 , Aug 17, 2019 |  BioCentury  |  Emerging Company Profile

Impact casting a wide synthetic lethality net

After laying the foundation with its PARP inhibitor, Impact plans to build a comprehensive synthetic lethality pipeline across known DNA damage repair targets and new ones outside of DDR to address a wider range of...
01:05 , Jun 28, 2019 |  BC Innovations  |  Translation in Brief

Banking on biomarkers for synthetic lethality

Repare thinks its biomarker-first approach could be a key differentiator for its synthetic lethal cancer drug programs. The company is collaborating with test developers ahead of time to recruit patients poised to benefit. Losing function...
03:07 , Jun 7, 2019 |  BC Innovations  |  Targets & Mechanisms

Following PARP, ATR axis next in line to expand synthetic lethal drug class

Promising ASCO readouts suggest targets in the ATR pathway are lining up behind PARP as the next drivers of “synthetic lethal” cancer killing. Biomarker and combination strategies presented at the American Society of Clinical Oncology...
22:01 , Mar 15, 2019 |  BioCentury  |  Product Development

Broadening the PARP playing field

With its latest clinical win for Lynparza, AstraZeneca is leading the field in stretching the use of PARP inhibitors beyond tumors that carry BRCA mutations. The results highlight one piece of a broader strategy companies...
16:11 , Oct 5, 2018 |  BC Week In Review  |  Clinical News

Ahead of ESMO data, Clovis' Rubraca dubbed a breakthrough for prostate cancer

Clovis Oncology Inc. (NASDAQ:CLVS) gained $2.25 to $31.39 on Oct. 2 after it said FDA granted breakthrough therapy designation for Rubraca rucaparib to treat metastatic castration resistant prostate cancer. The designation was based on initial...
19:01 , Oct 2, 2018 |  BC Extra  |  Company News

Ahead of ESMO data, Clovis' Rubraca dubbed a breakthrough for prostate cancer

Clovis Oncology Inc. (NASDAQ:CLVS) gained $2.25 to $31.39 on Tuesday after it said FDA granted breakthrough therapy designation for Rubraca rucaparib to treat metastatic castration resistant prostate cancer. The designation was based on initial data...
00:25 , Jun 16, 2018 |  BioCentury  |  Product Development

NSCLC disrupted

This year’s ASCO made clear that PD-1 inhibitors have supplanted chemotherapy as standard of care in first-line metastatic NSCLC. The unanticipated consequence is the knock-on effects for companies with studies under way in both first-...
15:20 , May 9, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Colorectal cancer; breast cancer Cell culture and mouse studies identified an imidazoquinolinone-based ATM inhibitor that could help treat colorectal cancer or triple-negative breast cancer (TNBC) in combination with Camptosar irinotecan or Lynparza olaparib, respectively....
03:45 , Apr 13, 2018 |  BC Innovations  |  Targets & Mechanisms

Meeting the burden

A major theme at this year’s AACR is the abundance of preclinical discovery driven by molecular signatures in patient samples, suggesting the research community is heeding the call for studies better grounded in human data,...
01:05 , Apr 21, 2017 |  BC Innovations  |  Product R&D

Making marks at AACR

Biomarkers that could stratify patients, point to treatment combinations or predict toxicity were a major part of the conversation at this year’s AACR conference, where they emerged as potential difference makers for a range of...